team 

REVOLUTIONARY DISCOVERY

The FundaMental Pharma Team harnesses the power of this revolutionary discovery of a new drug class to stop loss of brain structure and thus loss of function.

Company

FundaMental Pharma GmbH is a neuroscience company with portfolio at the preclinical stage, which was spun out of the Department of Neurobiology at Heidelberg University, Germany. First-in class NMDAR/TRPM4 (N/T) Interface Inhibitors selectively abolish extrasynaptic NMDARs-induced glutamate neurotoxicity but preserve the effects of synaptic NMDARs on neuronal survival and memory. N/T interface inhibition has the potential to stop neurodegeneration, to restore neuronal function, and to maintain brain health. N/T interface inhibitors provide neuroprotection through selective elimination of toxic extra synaptic NMDARs signaling.

Management Team

  • Dr. Dirk Beher (PhD)

    CEO

    Read Bio

  • Dr. Jing Yan (PhD)

    Senior Director
    of Research

    Read Bio

  • Dr. Alexander Straub (PhD)

    Head of
    Medicinal Chemistry

    Read Bio

  • Thomas Fink

    Head of Finance

    Read Bio

  • Dr. Thomas Schulze (PhD)

    Co-Founder &
    Advisor to the CEO

    Read Bio

  • Dr. Andy Jennings (PhD)

    Senior Consultant
    Computational Chemistry

    Read Bio

Board of Directors

Investors

Scientific Advisors

  • Melanie Leitner (PhD)

    Founder
    Accelerating Neuroventures, LLC

    Read Bio

  • Prof. Dr. med. Albert C. Ludolph

    University of Ulm

    Read Bio

  • Lynn Raymond, MD (PhD)

    University of British Columbia
    Vancouver

    Read Bio

Founders

  • Prof. Dr. Hilmar Bading

    University of Heidelberg

    Read Bio

  • Prof. Dr. Daniela Mauceri

    University of Marburg

    Read Bio

  • Dr. Thomas (PhD)

    Founder & Advisor to CEO

    Read Bio

  • Dr. Jing Yan (PhD)

    Senior Director of Reserarch

    Read Bio

Company history